Nov 5 (Reuters) - Glaxosmithkline Plc:
* Glaxosmithkline and XenoPort respond to FDA on Horizant(TM) for rls
* XenoPort Inc say FDA set a new prescription drug user fee act goal
date of April 6, 2011
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Glaxosmithkline Plc click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Glaxosmithkline and XenoPort respond to FDA on Horizant(TM) for rls
* XenoPort Inc say FDA set a new prescription drug user fee act goal
date of April 6, 2011
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Glaxosmithkline Plc click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.